Stryker Corporation $SYK Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 42.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 7,578 shares of the medical technology company’s stock after acquiring an additional 2,261 shares during the quarter. GAMMA Investing LLC’s holdings in Stryker were worth $2,386,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Sankala Group LLC acquired a new stake in shares of Stryker in the 4th quarter worth $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker during the fourth quarter worth about $28,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Barclays reduced their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. UBS Group began coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. Finally, Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Price Performance

SYK stock opened at $337.41 on Thursday. The business’s fifty day moving average price is $318.85 and its 200 day moving average price is $334.29. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $129.42 billion, a PE ratio of 34.97, a P/E/G ratio of 2.14 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.